You are here

  • Home
  • Archive
  • Volume 19, Issue 5
  • Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Article info

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Authors

  1. Correspondence to : Benjamin R Underwood, Beechcroft, Fulbourn Hospital, Cambridge, CB21 5EF, UK; ben.underwood{at}cpft.nhs.uk
View Full Text

Citation

Underwood BR, Fox C
Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects
BMJ Evidence-Based Medicine 2014;19:181.

Publication history

  • First published May 13, 2014.
Online issue publication 
September 15, 2014

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions